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Ultrasonographic evaluation of joint involvement in early
rheumatoid arthritis in clinical remission: power
Doppler signal predicts short-term relapse
Carlo A. Scire`1, Carlomaurizio Montecucco1, Veronica Codullo1, Oscar Epis1, Monica Todoerti1 and
Roberto Caporali1
Objectives. This study aimed to evaluate the usefulness of a systematic musculoskeletal ultrasonographic (US) assessment in the detection
of residual disease activity in patients with early RA who achieved clinical remission.
Methods. We prospectively studied 106 early RA patients receiving conventional DMARDs according to a disease activity score (DAS)-
steered therapeutic protocol over a 24-month period. Standard evaluation included clinical, laboratory, functional and systematic (44 joints)
US assessment. US indexes of grey scale (GS) and power Doppler (PD) synovitis were correlated with clinical evaluation, laboratory indexes
and clinical outcome. Clinical remission was defined when DAS was <1.6 at two consecutive visits 3 months apart.
Results. US examination was significantly more sensitive than clinical examination, both in active disease and in remission. In patients with
an active disease, both clinical and US indexes correlated with CRP, whereas in remission only PD still remained significantly correlated.
In clinical remission, 95% of the patients showed residual GS synovitis, and 41% of them showed a positive PD signal. Positive PD signal,
even in a single joint, resulted the main predictor of relapse within 6 months, both in univariable and multivariable logistic regression analysis.
Conclusions. In a cohort of early RA patients treated with conventional DMARDs, US-GS can detect residual disease activity more
sensitively than clinical examination both in active disease and in remission. Moreover, PD-positive synovial hypertrophy identifies an ongoing
inflammation even during remission and predicts short-term relapse.
KEY WORDS: Ultrasonography, Doppler, Arthritis, Rheumatoid, Early diagnosis, Prognosis, Treatment outcome, Disease activity, Remission.
Introduction
Remission is the current aim of the treatment in RA [1].
Several clinical trials have demonstrated that clinical remission
is a realistic end-point in RA allowing high remission rates,
mainly in early RA [2–7].
Remission is ideally regarded as the absence of detectable
disease and absence of structural and functional worsening over
time [8, 9]. Practically, clinical remission is defined as absent or
minimal disease activity, based on composite indexes including
physician’s and patient’s judgement, clinical evaluation and
laboratory indexes [10–13].
Even though several large perspective studies have shown that
a sustained clinical remission status does not averagely associate
with structural damage, some patients undergo structural and
functional worsening, suggesting an apparent dissociation
between disease activity and joint damage [8, 9]. Moreover, up
to 52% of the patients who have achieved clinical remission
undergo a disease exacerbation within 24 months suggesting
that a residual inflammation may persist under a clinically detect-
able disease activity level [8].
Based on these considerations, it is critical to find measures
that may predict a true disease remission both in terms of absence
of radiological progression and persistent absence of joint
inflammation.
Several efforts have been made to explain this subtle but
relevant issue mainly advocating ultra-sensitive measures of
joint inflammation, such as musculoskeletal ultrasonography
(US) or MRI [14, 15].
US is more sensitive and reliable than clinical examination, and
is better correlated with disease activity measures and structural
damage progression [16–22].
In particular, US-detected joint effusion (JE) or synovial hyper-
trophy (SH) and power Doppler (PD) signal at multiple joint
levels are valid disease activity markers in RA, modify after effec-
tive therapy and associate with a worsening in radiological scores
both in established and early active RA [16, 18, 21, 23]. In estab-
lished RA, US can also identify persistent inflammation even in
patients in clinical remission [24–26].
Despite this evidence, it is not currently known whether a
systematic ultrasonographic examination is useful in the assess-
ment of clinical remission in patients with early RA as compared
with standard clinical measures in terms of sensitivity, specificity
and predictivity of short-term relapse.
To explore the usefulness of US in evaluating clinical remission
in patients with early RA, we have investigated the relationship
between clinical and US measures and between US indexes and
acute phase reactants in a cohort of patients with early RA treated
with a disease activity score (DAS)-steered tight control therapeu-
tic protocol. Furthermore, we have evaluated the prognostic value
of US parameters in terms of persistent remission vs early relapse.
Patients and methods
Patient recruitment
Three hundred and twenty patients from the cohort attending the
Early Arthritis Clinic (EAC) of the Pavia University Hospital
from September 2004 to October 2006 were screened. Referral
criteria to the EAC included the presence of at least one of the
following signs or symptoms for 6 weeks to 1 year of duration:
(i) morning stiffness >30min, (ii) swelling of three or more joints
and (iii) swelling of less than three joints and positive squeezing
test of metacarpophalangeal or metatarsophalangeal joints [27].
After careful differential diagnosis, all patients fulfilling the
ACR criteria for RA [28] or presenting with a polyarthritis (PA)
not further classifiable [undifferentiated PA (UPA)] evolving in
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RA during the follow-up were included in the study and prospec-
tively evaluated for 24 months.
The study was approved by the local Ethical Committee of the
IRCCS Policlinico San Matteo Foundation of Pavia. Patient’s
written consent was obtained according to the Declaration of
Helsinki.
Patient assessment and treatment
One hundred and six patients underwent clinical evaluation at
baseline and 2, 4, 6, 9, 12, 15, 18, 21 and 24 months. Ritchie’s
Articular Index (RAI), a 44-joint swollen joint count (SJC),
patient global health assessment, HAQ, CRP, ESR and RF
were measured at every visit. The original DAS was calculated
for each patient at each time point [10]. Clinical remission was
defined when DAS was <1.6 at two consecutive visits 3 months
apart, after 512 months of follow-up. Relapse was defined as a
DAS 51.6 following a period of clinical remission. The prognos-
tic factors in UPA were scored according to Visser et al. [29]
A score 56 was considered as a poor prognostic index.
A tight control therapeutic protocol has been applied as fol-
lows: patients fulfilling RA criteria or UPA with poor prognostic
factors (n¼ 3) started with MTX 10mg/week, whereas the remain-
ing UPA patients started with HCQ 400mg/day. If after 2 months
the DAS was 52.4, DMARD therapy was modified as follows:
increase of MTX from 10 to 15mg/week or from HCQ
400mg/day to MTX 10mg/week. At each following visit, MTX
was escalated to a maximum dosage of 20mg/week if DAS> 2.4.
Patients who did not reach DAS <2.4 with the maximum
tolerated MTX dosage started anti-TNF- therapy. Steroid
(prednisone 12.5mg/day for 2 weeks and then 6.25mg/day) was
randomly assigned at baseline to half of the patients, as a part of
an open-label therapeutic study on the efficacy of low doses
of prednisone in early arthritis, approved by the local ethical
committee.
Five RA and two UPA patients did not accept the therapeutic
protocol at the study entry, and nine patients changed treatment
during follow-up due to MTX-related liver enzyme increase
(six patients) or steroid-related hyperglycaemia (two patients).
All these patients had regular clinical and US evaluations, were
included in the study and categorized by the baseline random
assignment.
US protocol
After clinical examinations, US assessment was performed at
baseline, and after 6, 12, 18 and 24 months by a single experienced
operator, unaware of clinical data, using a Toshiba Nemio scan-
ner with a multi-frequency linear array transducer (8–14MHz),
according to the European League Against Rheumatism
(EULAR) guidelines [30].
The US assessment included bilateral shoulder, elbow, wrist
(radiocarpal and midcarpal joint), MCP, PIP of the hands, ster-
noclavicular and acromioclavicular joint, knee, ankle and MTP
joints.
The US protocol included transverse and longitudinal scanning
of medial and lateral dorsal view of joint MCP, PIP and MTPs
with joint in extension; longitudinal and transverse scanning of the
dorsal aspect of the wrist (radio-carpal and mid-carpal joint) with
joint in neutral position; longitudinal and transverse scanning of
the supra-patellar recess, medial and lateral recesses of the knee in
extension; longitudinal and transverse scanning of the anterior
recess of the elbow, with joint in extended position; transverse
scanning of the posterior recess of the gleno-humeral joint with
the shoulder in neutral position; longitudinal and transverse scan-
ning of tibio-tarsal joint with the ankle in extended position; long-
itudinal and transverse scanning of sternoclavicular and
acromioclavicular joints.
Grey scale (GS) synovitis was defined as the presence
of joint effusion and/or SH. The presence of JE/SH was
identified in each joint as abnormal anechoic/hypoechoic IA
material according to the OMERACT definitions [31]. GS
synovitis was subjectively graded from 0 to 3 (0¼ normal;
1¼mild; 2¼moderate; 3¼marked) [32, 33]. The cut-off of
normality for different joints was defined according to Schmidt
et al. [34] taking into account that small effusion can be detectable
even in healthy subjects. In particular, the maximum dis-
tance from the bony surface and the capsule was 2mm for
MCP, PIP, wrists, and 4mm for knee according to Naredo
et al. [21], and 3mm for ankle, MTP, sterno-clavicular and
acromio-clavicular.
Synovial PD was assessed by selecting a region of interest that
included the bony margins, joint space and a variable view of
surrounding tissues (depending on the joint size).
PD calibrations were adjusted at the lowest permissible pulse
repetition frequency (PRF) to maximize sensitivity and were taken
as constant for the same joint in different patients.
Doppler frequency was set higher for the study of small joints
and superficial tissues, and lower for deep structures. Colour gain
was set just below the level that causes the appearance of noise
artefacts. Flow was demonstrated in two perpendicular planes
and confirmed by pulsed wave Doppler spectrum to exclude
artefacts [35].
The PD signal was subjectively graded on a semi-quantitative
scale from 0 to 3 (0¼ absence or minimal flow; 1¼mild: single
vessel signal; 2¼moderate: confluent vessels; 3¼marked: vessel
signals in >50% of the joint area) on the image with the maximal
enhancement on PD [21, 25, 35].
An overall US joint index for GS and PD signal was calculated
at each US assessment as the sum of GS or PD signal scores
obtained from each joint.
Each patient evaluation took 60min, and representative
images were archived.
Inter-observer reliability was evaluated by comparing the find-
ings of the two independent experienced rheumatologist ultraso-
nographers who performed US examinations of a series of
15 patients. Each examiner performed the US assessments inde-
pendently and sequentially. Intra-observer reliability was assessed
by blinded rescoring of the archived US images in the same subset
3 months after the respective real-time scanning.
Statistical analysis
Summary statistics of mean and S.D. or median and interquartile
range (IQR), when appropriate, were presented for continuous
variables. Differences between paired manually assessed SJC
and US-joint count (JC) were analysed by paired t-test.
Spearman’s or Pearson’s correlation coefficients were com-
puted to evaluate univariable associations among clinical, US
and laboratory variables based on their distribution.
To compare the hierarchical relationship between clinical and
US measures in the correlation with CRP, we performed a step-
wise multivariate linear regression including SJC, RAI, US-JC
and US-PD counts and scores. In such analysis, CRP values
were square transformed due to their skewed distribution.
To assess the value of clinical (SJC, RAI, CRP and ESR) and
US indexes (US-JC, US-GS score and US-PD count and score) at
the time of remission as predictors of relapse during the following
6 months of follow-up, we performed receiving operating curves
(ROCs) analyses.
The so-obtained best cut-off was applied to dichotomize
variables to be included in a subsequent multivariable logistic
regression analysis that explored the independent contribution
of each variable in the prediction of clinical relapse.
Inter-observer and intra-observer agreement was calculated by
an overall agreement (percentage of observed exact agreement),
-statistics [unweighted for dichotomous scoring (e.g. presence/
absence of synovitis); weighted for semi-quantitative scoring]
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and intra-class correlation coefficients (ICCs). A k-value of 0–0.20
was considered poor, 0.21–0.40 fair, 0.41–0.60 moderate,
0.61–0.80 good and 0.81–1.00 excellent [36].
All statistical tests were two-sided and were performed at
an -level of 0.05. Statistical analyses were performed using the
SPSS software (SPSS for Windows, Rel. 13.0. 2004, SPSS,
Chicago, IL, USA).
Results
Patients’ population
A total of 106 early RA patients were prospectively evaluated for
a follow-up period of 24 months.
The main baseline clinical, laboratory and US characteristics of
the early RA cohort are detailed in Table 1.
ACR criteria were fulfilled by 69% of the patients at baseline,
whereas all other patients fulfilled ACR criteria for RA during the
follow-up period. Roughly half of the patients were positive for
RF (58/106) at 24 months, whereas only 39% were positive
at baseline.
At the beginning of the study, all patients received DMARD
therapy, mainly MTX (68%), and HCQ (29%). Two patients
started with SSZ and one patient with CSA. Fifty-one patients
were assigned to receive steroidal therapy.
After 12 months, 96 patients were treated with MTX (average
dose 15mg/week), three patients with adalimumab (40mg every
other week) plus MTX, three patients with SSZ (2 g/day), two
with CSA (3mg/kg/day) and two patients were not receiving
DMARDs.
After 12 months of follow-up, 33 (35%) patients achieved
clinical remission, and 10 additional patients achieved remission
at 18 months.
US reliability
The inter-observer reliability assessment showed an exact agree-
ment of 78 and 93% for the presence/absence of GS synovitis and
for the PD signal, with k¼ 0.7 and 0.8, respectively. Using the
semi-quantitative grading system, the exact agreement was 62
and 86% for GS synovitis and for the PD signal, with weighted
k¼ 0.6 and 0.8 and ICC 0.8 and 0.9, respectively. The intra-
observer reliability assessment showed an exact agreement of
86 and 98%, with k¼ 0.7 and 0.9 for the presence/absence of
GS synovitis and for the PD signal, respectively. Using the
semi-quantitative grading system, exact agreement was 82 and
96%, with weighted k¼ 0.8 and 0.9 and ICC 0.9, both for GS
synovitis and PD signal, respectively.
Relationship between US and clinical or laboratory
measures of disease activity
At baseline, US-JC showed a significant correlation with SJC
(r¼ 0.7, P< 0.001) but it detected more involved joints than
paired clinical examination (16.5 9.7 vs 12.5 7.6, P< 0.001).
In remission, the difference became even more significant
(6 4.3 vs 2.6 2, P< 0.0001) and the correlation decreased to
0.4 (P< 0.01) (Fig. 1).
In clinical remission, 41 (95%) out of 43 patients showed
persistent joint involvement by US-JC and 18 (41%) out of 43
showed a positive PD signal. In these cases, US-JC ranged
FIG. 1. Comparison and correlation between clinical SJC and US-JC in active disease (A) and in remission (B).
TABLE 1. Summary of baseline patients’ characteristics
No. of patients 106
Age, mean S.D., years 59.514.4
Sex, males:females 31:75
Disease duration, mean S.D., months 3.82.8
ACR criteria, n 73/106
DAS, mean S.D. 3.51
HAQ, mean S.D. 1.20.8
SJC (44 joints), mean S.D. 12.57.6
RAI, mean S.D. 7.15.3
GH assessment (0–100), mean S.D. 60.519.2
ESR, mean S.D., mm/h 31.822.4
CRP, mean S.D., mg/dl 1.92.4
RF positive, n (%) 41/106 (39)
ACPA positive, n (%) 30/103 (29)
Shared epitope, n (%) 35/93 (38)
Starting with MTX, n 72
Starting with HCQ, n 31
Starting with Prednisone, n 48
ACPA: anti-citrullinated peptide antibodies. GH: general health.
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from 1 to 17 (median value 6) and PD count from 1 to 5 (median
value 1.5) (Fig. 2).
The correlations between clinical or US measures and ESR or
CRP are reported in Table 2.
At baseline, both SJC and US indexes were significantly corre-
lated with ESR and CRP, whereas in remission only PD measures
are still found to be correlated with CRP.
Clinical and US predictors of sustained remission
Out of 43 patients achieving clinical remission, 14 showed disease
relapse during the next 6 months. The DAS at remission was
significantly higher in the patients who had a short-term relapse
(mean 1.4 0.2 vs 1 0.3, P< 0.05) as was the SJC [median (IQR)
SJC 3 (2–6) vs 1 (0–3); P< 0.05). Conversely, the number of tender
joints, ESR and CRP did not differ between the two groups.
Furthermore, the relapse rate was slightly lower in patients
taking steroids, but this difference did not reach statistical signifi-
cance (7/26 vs 7/17, P¼ 0.51).
PD count and US-JC were significantly higher in patients who
relapsed: median (IQR) PD score 1 (1–2.5) vs 0 (0-0), and median
(IQR) US-JC 6 (11–13) vs 2 (4–6.75) (all P< 0.05).
The cut-off values for each significant variable calculated from
the ROC curves were: PD count> 0, US-JC> 2, DAS> 1.10
and SJC> 1. Based on these cut-off values, all variables were
dichotomized and a multivariable binary logistic regression was
performed.
The positivity of PD signal (at least at one site) resulted the
main predictor of disease relapse in patients in clinical remission,
even after adjustment for steroid medication (Table 3).
The area under the ROC curve for PD count was 0.8. A positive
PD signal showed 85.7% sensitivity (95% CI¼ 57.2, 97.8) and
82.8% specificity (95% CI¼ 64.2, 94.1) for early relapse, with a
positive predictive value of 70.6% and a negative predictive value
of 92.3% (Fig. 3).
Discussion
In early RA patients who achieved clinical remission after a
DAS-steered therapeutic strategy with conventional DMARDs,
the results of the present study indicate that: (i) US is much
more sensitive than clinical examination in the assessment of
joint involvement; (ii) PD variables correlate with CRP in remis-
sion, whereas clinical parameters do not; and (iii) persistence of a
positive PD signal in a single joint is the main independent pre-
dictor of early relapse.
Our study population included a homogeneous inception
cohort of patients with early RA prospectively evaluated through
the first 2 years of disease. Disease duration on average at the first
evaluation was <4 months, allowing ample opportunity to modify
the disease course by an intensive therapeutic protocol [37]. The
therapeutic strategy adopted in our cohort included a step-up
DMARD titration followed by TNF- inhibitors. None of the
FIG. 2. Persistence of US-detected synovitis in early RA patients in clinical remission (A) GS synovitis and (B) PD synovitis.
TABLE 2. Correlations between clinical or US measures and disease activity
indexes at baseline and in remission after 1 year
Baseline Remission
Parameters ESR CRP ESR CRP
RAI 0.14 0.04 0.14 0.01
SJC 0.39x 0.34x 0.11 0.03
US-JC 0.41x 0.32 0.04 0.08
US-GS score 0.44x 0.37x 0.09 0.17
US-PD count 0.47x 0.34x 0.21 0.26
US-PD score 0.43x 0.36x 0.21 0.28
Spearman’s  correlation coefficients are presented. xP< 0.01; P< 0.05.
TABLE 3. Association between clinical and US findings at remission and the
occurrence of clinical relapse within 6 months
No relapse, n¼29 Relapse, n¼ 14 OR 95% CI
DAS > 1.1 13 11 9 0.7, 110.3
SJC > 1 13 9 0.6 0.1, 5.5
US-JC > 2 10 11 4.6 0.4, 49.5
US-PD > 0 5 12 12.8 1.6, 103.5
Steroid 19 7 0.7 0.1, 4.4
The cut-off values were calculated by ROC curve analysis. P< 0.05. OR: odds ratio.
FIG. 3. PD-positive joints and occurrence of clinical relapse. (A) ROC curve for the
number of involved joints. (B) Frequency of relapse according to the positive or
negative PD status.
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patients who achieved clinical remission at 12 and 18 months had
received TNF- inhibitors. Therefore, all inferences about the
quality of remission refer to a DMARD-induced remission.
Our definition of DAS-based remission is more stringent than
the original one, requiring a remission status detectable at two
consecutive visits after at least 1 year of DMARD therapy [10].
This reflects the need to exclude very short-lasting remissions or
purely accidental low DAS calculations, in order to plan a possi-
ble step-down therapeutic strategy in those patients achieving
remission. However, persistent PD signal and relapse are signifi-
cantly associated when remission is calculated at a single time
point (data not shown).
The remission rate we observed was similar to that reported
in different RA cohorts treated with similar therapeutic strate-
gies [2, 5, 37]. Relapse rate was 30% after 6 months in
our series. This result is also consistent with data found in
established RA [8].
Previous studies have indicated US as a good disease activity
marker, sensitive to change after effective treatments [16, 21,
38, 39]. Our prospective study provides the first evidence of the
predictive value of PD analysis in terms of sustained clinical
response in patients with early RA. A recent study by Brown
et al. [26] has indicated that PD associates with a 1-year radiolog-
ical progression in clinical remission in established RA. On
the other hand, persistent clinical remission is associated with
a minimal radiological progression rate, whereas the most relevant
characteristic associating with radiological progression is the
concurrent exacerbation of RA [8].
Our data complete these findings, demonstrating that PD
synovitis is a good predictor of unstable remission, which may
explain the ongoing structural damage associated with a positive
PD signal.
An important finding in our study is the high negative predic-
tive value of the PD assessment. Indeed, a negative PD signal
associates with stable remission in >90% of the cases supporting
the concept that a more complete remission might be defined by a
negative PD finding. Moreover, once a stable clinical remission
has been achieved, we could speculate that a step-down therapeu-
tic strategy might be limited to patients with a negative PD signal.
A new aspect arising from this study is the modification of
the relationship between US and clinical parameters according
to different disease activity levels. A systematic joint examination
allowed a direct comparison between manual joint count and US
joint count. The diminishing strength of the correlation between
the manual joint count and US joint count in remission suggests
that the former has a quite insensitive trend during the disease
course compared with US as a measure of joint inflammation.
Indeed, 95% of the patients in remission showed a US-JC> 0
and 41% had at least one positive PD signal by systematic joint
assessment. These results in early RA are similar to those obtained
in a cohort of established RA in DMARD-induced clinical remis-
sion by assessing hands and wrists: 73% of the patients showed a
GS-SH and 43% a positivity of PD [25]. The higher values of GS
synovitis in our cohort may be related to the higher number of
joints evaluated (44 joints vs wrist/MCP joints), or to technical
differences of the US equipment. In any case, the frequency of PD
signal was comparable, suggesting that the most relevant joints for
PD are included in wrists and MCPs. This is also supported by the
evidence that a simplified US-PD evaluation is the predictive of
radiographic progression in patients who achieved remission [26].
Thus, even though a direct validation of the best subset of joints
to evaluate is not yet formally defined in patients in clinical remis-
sion, a simplified and less time-consuming joint count that
includes wrist and MCP joints seems to be suitable for monitoring
joint inflammation in this setting [26].
In our study, we also demonstrated a specific relationship of
PD synovitis with an inflammatory index such as CRP. The
strength of this correlation is quite weak and it should be regarded
with caution. However, it is consistent with the generally accepted
view that PD is a specific marker of active synovitis, correlating
with systemic inflammation [18, 40].
The present study does have some limitations. The first one is
related to US analysis that can be regarded as poorly standardized
and operator dependent. In our study, the OMERACT definitions
of JE, SH and PD signal were adopted, and a wide joint assess-
ment was performed in order to maximize the sensitivity in
patients with very low disease activity. All patients were evaluated
by the same operator, blinded to clinical data, who showed good
to excellent intra-reader reliability for PD and GS indexes. Also
inter-observer reliability scored good to excellent using this
approach, suggesting that these results are reproducible in a
routine clinical setting. Clearly, the machine-related sensitivity
might affect reproducibility in terms of strength of the results if
different technical equipment is employed.
A second limitation refers to the study population including at
baseline both RA and UPA patients. One could speculate that
stable remission is more likely in those presenting with UPA
and that a positive PD signal is more likely in those presenting
with RA, so that the inverse relationship between stable remission
and positive PD signal might be spurious. As a matter of fact,
lower PD activity and higher remission rate was found in those
patients with UPA who did not develop RA criteria and who were
excluded from the study (data not shown).
In our study population, 70% of the patients fulfilled the RA
criteria at baseline, and this finding was not independently asso-
ciated either with the remission rate or with the percentage of PD
positive synovitis.
In conclusion, our data support the specific role of US in
detecting residual disease activity in early RA. PD-positive
synovitis identifies subclinical synovial inflammation in a sensitive
and specific way, and also predicts clinical outcome. Available
data are now sufficient to test PD in therapeutic decisions, both
as a marker of residual activity in patients achieving remission and
as a marker of relapsing disease during a clinical remission period.
PD monitoring in daily practice might lead to increase remission
rates and to reduce disease relapses and structural damage
progression of patients with early RA.
Rheumatology key messages
 Musculoskeletal US identifies subclinical synovitis in early RA.
 PD is specifically associated with ongoing subclinical inflamma-
tion.
 In clinical remission, PD signal predicts short-term relapse.
Disclosure statement: The authors have declared no conflicts of
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